FluGen

Focus: FluGen is a Madison-based biotechnology company focused on developing innovative vaccines and adjuvants for infectious diseases, primarily influenza. The company operates as a pre-revenue biotech with an early-stage pipeline of live attenuated influenza vaccine candidates.

Vaccines Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About FluGen

AI assessmentNot Hiring

No open roles listed right now. Follow FluGen to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

FLUGEN 101.2 device

Influenza

N/A

Clinical Trials (1)

NCT01767337Intracutaneous Delivery of Varied Dose Volumes of Saline

N/A

Help build intelligence for FluGen

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage vaccine platform with focused therapeutic area (influenza/infectious diseases) offers the chance to contribute to foundational science in an underexplored modality space
Location in Madison, Wisconsin provides lower cost-of-living and access to academic partnerships (University of Wisconsin) for R&D collaboration
Pre-revenue stage means potential for meaningful equity upside and direct impact on clinical decision-making if pipeline advances

Watch Out For

Zero active job openings and sparse public hiring data suggest minimal near-term expansion or uncertainty in headcount planning
Early-stage pipeline (5 total trials, all Phase 1) with no revenue, products, or published clinical data limits near-term validation risk and career trajectory visibility

Generated by Claude from FluGen's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Injection to deltoid

Intracutaneous Drug Delivery

N/A

Clinical Trials (1)

NCT01767324Site Selection for Intracutaneous Saline Delivery

N/A

Sing2016 M2SR H3N2 influenza vaccine

Influenza Vaccine

Phase 1

Clinical Trials (1)

NCT04785794Safety and Immunogenicity of the Sing2016 M2SR H3N2 Monovalent Influenza Vaccine in Adults Ages 50 to 85 Years Old

Phase 1